

33rd Pezcoller Symposium

June 13-14, 2022 – Auditorium of Humanities
Department, University of Trento,
Via Tommaso Gar, 14, Trento



What are the obstacles to cancer immunotherapy success?

Moderators:

Bardelli Alberto

Briskin Cathrin

d'Adda di Fagagna Fabrizio

Del Sal Giannino

Draetta Giulio

Loda Massimo

Mantovani Alberto

Piccolo Stefano

Rescigno Maria

Day 1 – Monday, June 13, 2022

* Central European Time (CEST)

8.00 *Registration*

8.30 *Welcome* Enzo Galligioni

8.40 *Focus and Goals* Stefano Piccolo

8.50 *David M. Livingston Lecture:*

William G. Kaelin (*Nobel Laureate, Dana Farber Cancer Institute*)

9.35 *Discussion led by Stefano Piccolo*

9.50 *Keynote Lecture 1: Laurie H.*

Glimcher (*Dana Farber Cancer Institute*) IL-22 Blockade as a Therapeutic Modality for Blood Disorders

10.35 *Discussion led by Massimo Loda*

10.50 Coffee break & poster exhibition

11.05 *Session 1: New Immunotherapeutic*

Approaches Moderator: Cathrin Briskin

11.05 **Chiara Bonini** (Università Vita Salute S. Raffaele, Milan)

Genome editing for cancer immunotherapy

11.30 *Discussion*

11.45 **Philip J. Kranzusch** (Harvard Medical School; Dana-Farber Cancer Institute)
cGAS-like receptors reveal new signals controlling innate immunity

12.10 *Discussion*

12.25 **Jamie B. Spangler** (John's Hopkins University School of Medicine)

Mechanism-driven design of antibodies for cancer immunotherapy

12.50 *Discussion*

13.05 Lunch & poster exhibition

14.05 *Session 2: New Clinical Observations involving Immunotherapy*

Moderator: Giulio F. Draetta

14.05 **Elizabeth M. Jaffee** (John's Hopkins University School of Medicine)

Progress in converting pancreatic cancer into an immunologic disease: Lessons learned from the clinic

14.30 *Discussion*

14.45 **Emile E. Voest** (NKI, Amsterdam)

Integrating genomics and autologous tumor models to advance precision treatment

15.10 *Discussion*

15.25 *Session 3: Metabolism and Immunotherapeutics*

Moderator: Giannino Del Sal

15.25 *Jorge Moscat* (Weill Cornell Medical College) Targeting the tumor stroma to overcome immunotherapy resistance: The colorectal cancer paradigm

15.50 *Discussion*

16.05 *Erika L. Pearce* (John's Hopkins University School of Medicine)
Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function

16.30 *Discussion*

16.45 *Matthew Vander Heiden* (MIT)

How tissue nutrient availability influences cancer progression and immunity

17.10 *Discussion*

17.25 End of Day 1

20.00 Symposium dinner

Grand Hotel Trento, P.za Dante, 20

Day 2 – Tuesday, June 14, 2022

* Central European Time (CEST)

8.30 *Keynote Lecture 2: Philip D. Greenberg*

(Fred Hutchinson Cancer Research Center)

Adoptive therapy with engineered T cells: Designing T cells for success

9.15 *Discussion led by Maria Rescigno*

9.30 *Session 4: Innate Immunity*

Moderator: Fabrizio d'Adda di Fagagna

9.30 *Caetano Reis e Sousa*

(Francis Crick Institute, UK)

Necrophagia, DaNGeRous indigestion and immunity to cancer

9.55 *Discussion*

10.10 *Andrea Ablasser* (EPFL, Lausanne)

The cGAS-STING pathway and its impact in cancer

10.35 *Discussion*

10.50 Coffee break and poster exhibition

11.10 *Session 5: Bacteria and Cancer Immunity*

Moderator: Alberto Bardelli

11.10 *Yardena Samuels* (Weizmann Institute of Science, Israel)

Identifying the highly complex intra-tumor heterogeneity in melanoma

11.35 *Discussion*

11.50 *Richard A. Flavell* (Department of Immunobiology, Yale School of Medicine)

Personalized modeling of human cancer in humanized mice

12.15 *Discussion*

12.30 Lunch and poster exhibition

13.30 *Poster Session and Maria Begnudelli Awards to the 3 best posters*

Led by Massimo Loda

14.15 *Session 6: Why do Immunotherapies fail*
Moderator: Alberto Mantovani

14.15 *Antoni Ribas* (UCLA-Broad Stem cell research center)

Mechanisms of response and resistance to PD-1 blockade therapy

14.40 *Discussion*

14.55 *Padmanee Sharma* (MD Anderson Cancer Center)

From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

15.20 *Discussion*

15.35 *Charles L. Sawyers* (MSKCC)

Tumor Microenvironment in Prostate Cancer

16.00 *Discussion*

16.15 *Closing Remarks* by *Alberto Mantovani*

16.30 End of Day 2